Evidence map›Paper›PMID 37864060›Full record

ArticlePain and therapy2023

Combined Efficacy of Systemically Acting Diclofenac Sodium Patch and Alpha-2-Delta Calcium Channel Ligand in Chronic Low Back Pain: Subanalysis of a Phase III Study.

Shigeki Yamaguchi, Takaaki Terahara, Koji Okawa, Hiroshi Inakura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shigeki YamaguchiDepartment of Anesthesia and Pain Medicine, Dokkyo Medical University School of Medicine, Tochigi, Japan.
Takaaki TeraharaHisamitsu Pharmaceutical Co., Inc, 2-4-1, Marunouchi, Chiyoda-Ku, Tokyo, 100-6330, Japan.
Koji OkawaHisamitsu Pharmaceutical Co., Inc, 2-4-1, Marunouchi, Chiyoda-Ku, Tokyo, 100-6330, Japan.
Hiroshi InakuraHisamitsu Pharmaceutical Co., Inc, 2-4-1, Marunouchi, Chiyoda-Ku, Tokyo, 100-6330, Japan. hiroshi_inakura@hisamitsu.co.jp.ORCID http://orcid.org/0000-0001-9771-797X
Hisamitsu Pharmaceutical (Japan) · JPDokkyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic low back pain often comprises mixed pain types and involves multiple factors. Therefore, we hypothesized that the systemic transdermal formulation of diclofenac sodium (DF systemic patch), which is effective for nociceptive pain, and an α2δ Ca

methodsFrom among participants in a randomized, double-blind, placebo-controlled study of DF systemic patch (75 or 150 mg) applied once daily for 2 weeks in patients with chronic low back pain, we performed a subpopulation analysis of those who were concomitantly treated with an α2δ Ca

resultsThe difference (95% confidence interval) in the least square mean pain VAS score between patients in the 150-mg combination group, who were treated with 150-mg DF systemic patch and an α2δ Ca

conclusionsThe combination of the DF systemic patch and an α2δ Ca TRIAL REGISTRATION NUMBERS: JPRN-JapicCTI-205134 and jRCT2080225040.

Indexed as

Additive effectsDiclofenac sodiumLow back painNeuropathic painNSAIDsRandomized controlled trialSystemic actionTransdermal formulationVisual analog scale (VAS)α2δ Ca2+ channel ligands

Identifiers

PMID37864060
PMCPMC10616048
OpenAlexW4387823763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.